These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

185 related articles for article (PubMed ID: 30174281)

  • 1. Assessing statin effects on cardiovascular pathways in HIV using a novel proteomics approach: Analysis of data from INTREPID, a randomized controlled trial.
    Toribio M; Fitch KV; Stone L; Zanni MV; Lo J; de Filippi C; Sponseller CA; Lee H; Grundberg I; Thompson MA; Aberg JA; Grinspoon SK
    EBioMedicine; 2018 Sep; 35():58-66. PubMed ID: 30174281
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pitavastatin versus pravastatin in adults with HIV-1 infection and dyslipidaemia (INTREPID): 12 week and 52 week results of a phase 4, multicentre, randomised, double-blind, superiority trial.
    Aberg JA; Sponseller CA; Ward DJ; Kryzhanovski VA; Campbell SE; Thompson MA
    Lancet HIV; 2017 Jul; 4(7):e284-e294. PubMed ID: 28416195
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Differential Plasma Protein Regulation and Statin Effects in Human Immunodeficiency Virus (HIV)-Infected and Non-HIV-Infected Patients Utilizing a Proteomics Approach.
    deFilippi C; Toribio M; Wong LP; Sadreyev R; Grundberg I; Fitch KV; Zanni MV; Lo J; Sponseller CA; Sprecher E; Rashidi N; Thompson MA; Cagliero D; Aberg JA; Braun LR; Stanley TL; Lee H; Grinspoon SK
    J Infect Dis; 2020 Aug; 222(6):929-939. PubMed ID: 32310273
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effects of pitavastatin and pravastatin on markers of immune activation and arterial inflammation in HIV.
    Toribio M; Fitch KV; Sanchez L; Burdo TH; Williams KC; Sponseller CA; McCurdy Pate M; Aberg JA; Zanni MV; Grinspoon SK
    AIDS; 2017 Mar; 31(6):797-806. PubMed ID: 28252528
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pitavastatin: novel effects on lipid parameters.
    Chapman MJ
    Atheroscler Suppl; 2011 Nov; 12(3):277-84. PubMed ID: 22152282
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Greater remnant lipoprotein cholesterol reduction with pitavastatin compared with pravastatin in HIV-infected patients.
    Joshi PH; Miller PE; Martin SS; Jones SR; Massaro JM; D'Agostino RB; Kulkarni KR; Sponseller C; Toth PP
    AIDS; 2017 Apr; 31(7):965-971. PubMed ID: 28121706
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effects of Pitavastatin on Coronary Artery Disease and Inflammatory Biomarkers in HIV: Mechanistic Substudy of the REPRIEVE Randomized Clinical Trial.
    Lu MT; Ribaudo H; Foldyna B; Zanni MV; Mayrhofer T; Karady J; Taron J; Fitch KV; McCallum S; Burdo TH; Paradis K; Hedgire SS; Meyersohn NM; DeFilippi C; Malvestutto CD; Sturniolo A; Diggs M; Siminski S; Bloomfield GS; Alston-Smith B; Desvigne-Nickens P; Overton ET; Currier JS; Aberg JA; Fichtenbaum CJ; Hoffmann U; Douglas PS; Grinspoon SK;
    JAMA Cardiol; 2024 Apr; 9(4):323-334. PubMed ID: 38381407
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Rationale and design of the Randomized Trial to Prevent Vascular Events in HIV (REPRIEVE).
    Grinspoon SK; Fitch KV; Overton ET; Fichtenbaum CJ; Zanni MV; Aberg JA; Malvestutto C; Lu MT; Currier JS; Sponseller CA; Waclawiw M; Alston-Smith B; Cooper-Arnold K; Klingman KL; Desvigne-Nickens P; Hoffmann U; Ribaudo HJ; Douglas PS;
    Am Heart J; 2019 Jun; 212():23-35. PubMed ID: 30928825
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Statins for atherosclerotic cardiovascular disease prevention in people living with HIV in Thailand: a cost-effectiveness analysis.
    Boettiger DC; Newall AT; Chattranukulchai P; Chaiwarith R; Khusuwan S; Avihingsanon A; Phillips A; Bendavid E; Law MG; Kahn JG; Ross J; Bautista-Arredondo S; Kiertiburanakul S
    J Int AIDS Soc; 2020 Jun; 23 Suppl 1(Suppl 1):e25494. PubMed ID: 32562359
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comparison of the lipid-lowering effects of pitavastatin 4 mg versus pravastatin 40 mg in adults with primary hyperlipidemia or mixed (combined) dyslipidemia: a Phase IV, prospective, US, multicenter, randomized, double-blind, superiority trial.
    Sponseller CA; Morgan RE; Kryzhanovski VA; Campbell SE; Davidson MH
    Clin Ther; 2014 Aug; 36(8):1211-22. PubMed ID: 24998014
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Rationale and design of the Mechanistic Substudy of the Randomized Trial to Prevent Vascular Events in HIV (REPRIEVE): Effects of pitavastatin on coronary artery disease and inflammatory biomarkers.
    Hoffmann U; Lu MT; Olalere D; Adami EC; Osborne MT; Ivanov A; Aluru JS; Lee S; Arifovic N; Overton ET; Fichtenbaum CJ; Aberg JA; Alston-Smith B; Klingman KL; Waclawiw M; Burdo TH; Williams KC; Zanni MV; Desvigne-Nickens P; Cooper-Arnold K; Fitch KV; Ribaudo H; Douglas PS; Grinspoon SK;
    Am Heart J; 2019 Jun; 212():1-12. PubMed ID: 30928823
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A proteomic approach for investigating the pleiotropic effects of statins in the atherosclerosis risk in communities (ARIC) study.
    Bohn B; Lutsey PL; Tang W; Pankow JS; Norby FL; Yu B; Ballantyne CM; Whitsel EA; Matsushita K; Demmer RT
    J Proteomics; 2023 Feb; 272():104788. PubMed ID: 36470581
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Differences in statin utilization and lipid lowering by race, ethnicity, and HIV status in a real-world cohort of persons with human immunodeficiency virus and uninfected persons.
    Riestenberg RA; Furman A; Cowen A; Pawlowksi A; Schneider D; Lewis AA; Kelly S; Taiwo B; Achenbach C; Palella F; Stone NJ; Lloyd-Jones DM; Feinstein MJ
    Am Heart J; 2019 Mar; 209():79-87. PubMed ID: 30685678
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effects of Pitavastatin on Lipid Profiles in HIV-Infected Patients with Dyslipidemia and Receiving Atazanavir/Ritonavir: A Randomized, Double-Blind, Crossover Study.
    Wongprikorn A; Sukasem C; Puangpetch A; Numthavej P; Thakkinstian A; Kiertiburanakul S
    PLoS One; 2016; 11(6):e0157531. PubMed ID: 27304841
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Angiotensin converting enzyme inhibitor and HMG-CoA reductase inhibitor as adjunct treatment for persons with HIV infection: a feasibility randomized trial.
    Baker JV; Huppler Hullsiek K; Prosser R; Duprez D; Grimm R; Tracy RP; Rhame F; Henry K; Neaton JD
    PLoS One; 2012; 7(10):e46894. PubMed ID: 23082133
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A randomized, double-blind trial comparing the efficacy and safety of pitavastatin versus pravastatin in patients with primary hypercholesterolemia.
    Saito Y; Yamada N; Teramoto T; Itakura H; Hata Y; Nakaya N; Mabuchi H; Tushima M; Sasaki J; Ogawa N; Goto Y
    Atherosclerosis; 2002 Jun; 162(2):373-9. PubMed ID: 11996957
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Are all statins the same? Focus on the efficacy and tolerability of pitavastatin.
    da Silva PM
    Am J Cardiovasc Drugs; 2011; 11(2):93-107. PubMed ID: 21446776
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Rationale, design features, and baseline characteristics: The Heart Institute of Japan-PRoper level of lipid lOwering with Pitavastatin and Ezetimibe in acute coRonary syndrome (HIJ-PROPER).
    Kawada-Watanabe E; Ogawa H; Koyanagi R; Arashi H; Yamaguchi J; Matsui K; Hagiwara N
    J Cardiol; 2017 Mar; 69(3):536-541. PubMed ID: 27349705
    [TBL] [Abstract][Full Text] [Related]  

  • 19. HMG-CoA reductase inhibitor (Statin) therapy and coronary atherosclerosis in Japanese subjects: role of high-density lipoprotein cholesterol.
    Tani S; Nagao K; Hirayama A
    Am J Cardiovasc Drugs; 2011 Dec; 11(6):411-7. PubMed ID: 22149320
    [TBL] [Abstract][Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 10.